Last reviewed · How we verify

NCT04113499: DESTIN

Endoscopic Necrosectomy Versus Step-up Endoscopic Intervention

Completed NA Last updated 12 July 2023
What this trial tests

NA trial testing Direct Endoscopic Intervention in Pancreatic Necrosis in 11 participants. Completed in 25 April 2022.

Timeline
27 November 2019
Primary endpoint
25 April 2022
25 April 2022

Quick facts

Lead sponsorAdventHealth
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment11
Start date27 November 2019
Primary completion25 April 2022
Estimated completion25 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

AdventHealth — full company profile →

Who can join

18 and older, any sex, with Pancreatic Necrosis or Necrosis Pancreas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is to compare clinical outcomes between patients undergoing immediate endoscopic necrosectomy compared to step-up endoscopic interventions in patients undergoing endoscopic therapy for infected necrotizing pancreatitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.
    Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, et al · · 2024 · cited 48× · PMID 37980922 · DOI 10.1016/s2468-1253(23)00331-x

Verify or expand the search:

Other recruiting trials for Pancreatic Necrosis

Currently open trials in the same condition.

Other AdventHealth trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04113499.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing